25 Aug 2020 --- Chr. Hansen’s new 2025 strategy will see more investments in the expansion of its microbial platform and technological capabilities. Notably, the Denmark-based company is allocating approximately three-quarters of its R&D spending during this strategy period toward new product development. Growth is also set to be achieved via bolt-on acquisitions, especially within the Health & Nutrition space. During the strategy period the supplier’s longer-term financial ambition is to deliver mid- to high single-digit organic growth, averaged over the period.
